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Introduction: C1q is an essential part of the classical pathway of complement activation.
Genetic deficiencies, caused by homozygous mutations in one of the C1q genes, are rare
and are strongly associated with development of systemic lupus erythematosus (SLE).
Here we describe a C1q-deficient patient with a compound heterozygous
mutation. Material and methods: Serum was analysed with enzyme-linked immunosorbent
assay (ELISA) and Western blot for the presence of C1q, and DNA and RNA sequencing
was performed to identify the mutations and confirm that these were located on different
chromosomes. Results: The medical history of the patient includes SLE diagnosis at age 11
years with cerebral involvement at age 13, various infections, osteonecrosis and hemophago-
cytic syndrome. Using ELISA and Western blot, we confirmed the absence of C1q in
the serum of the patient. Using DNA sequencing, two mutations in the C1QC gene were
identified: c.100G>A p.(Gly34Arg) and c.205C>T p.(Arg69X). With RNA sequencing we
confirmed that the mutations are located on different chromosomes. Discussion: The patient
described in this case report has a compound heterozygous mutation in C1QC resulting in C1q
deficiency. Lupus (2019) 28, 1255–1260.
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Introduction
The complement system consists both of soluble
and membrane-bound proteins. Activation can
occur via three different pathways: the classical
pathway (CP), the lectin pathway and the alterna-
tive pathway. The CP is activated when C1q is
bound to immunoglobulin M (IgM), IgG immuno-
complexes or pentraxins.1 Many complement pro-
teins are produced by hepatocytes, but cells of the
immune system also produce several complement
proteins.2 Importantly, C1q is produced not by
hepatocytes but largely by cells of myeloid lineage.
C1q has been described to have other functions
outside the complement system cascade: in the
remodelling of the maternal decidua during preg-
nancy, during embryonic development, in neuro-
logical synapse function and in the coagulation
process.3 The C1q protein is a molecule of
480 kDa that has six identical arms. Each arm con-
sists of three combined peptide chains: A, B and C.
These peptide chains are generated from three dif-
ferent genes: C1QA, C1QB and C1QC, which have
a synchronized transcription.4
C1q deficiency is a rare condition with more than
70 documented cases from at least 45 different
families.5 These deficiencies all are the result of
homozygous mutations in one of the three C1q
genes, except in one case with a compound hetero-
zygous mutation in C1QA.6 Patients with C1q defi-
ciency have various clinical presentations and
outcomes.7 Most common is the diagnosis of sys-
temic lupus erythematosus (SLE) in early child-
hood and recurrent infections.6–8 Other common
clinical manifestations are alopecia, Raynaud phe-
nomenon, and involvement of the central nervous
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system, and Sjo¨gren syndrome and hyper-IgM syn-
drome have been reported.5–7 Treatment of C1q-
deficient patients mainly focuses on the treatment
of symptoms. For combating the C1q deficiency
itself, intravenous administration of fresh frozen
plasma (FFP) is used. In rare cases allogenic hem-
atopoietic stem cell transplantation has been
performed.9,10
Here we describe a patient with C1q deficiency
based on a compound heterozygous mutation in
the C1QC gene. This patient was treated with
FFP for more than a decade; over time it has
resulted in various adverse reactions ranging from
mild to anaphylactic, which led to discontinuation
of the FFP therapy.
Material and methods
Patient
The patient is a 29-year-old Dutch woman diag-
nosed with C1q deficiency since early childhood.
Blood was obtained from the patient on signing
an informed consent in compliance with the
Declaration of Helsinki.
Samples
Blood was collected from the patient to obtain
serum as well as peripheral blood mononuclear
cells (PBMCs) using Ficoll-Paque density gradient
centrifugation.
Western blot
With Western blot the availability of C1q was
examined by detection of the three chains of the
C1q protein. Serum from the patient and normal
human serum (NHS), which was used as a positive
control, were applied in reduced and non-reduced
sodium dodecyl sulphate conditions. Western blot
was performed using previously described
methods.11
Enzyme-linked immunosorbent assay (ELISA)
C1q measurement by an in-house–developed
ELISA was performed as previously described.12
In short, plates were coated with mouse anti-
human C1q ((2204), Nephrology Department,
Leiden University Medical Center (LUMC)) in
coating buffer (0.1 M Na2CO3, 0.1 M NaHCO3,
pH 9.6), samples were incubated at 37C and detec-
tion was performed with rabbit anti-human C1q
(Dako catalogue no. A0136) for one hour at 37C
and subsequently a goat anti-rabbit horseradish
peroxidase (Dako catalogue no. P0448), also incu-
bated for one hour at 37C. The substrate was
added to the plates using 2,2’-azino-bis-3-ethyl
benzthiazoline-6-sulphonic acid, and the signal
was measured at an absorbance level of 415 nm
using a Biorad iMark Microplate Absorbance
Reader.
RNA isolation and complementary DNA (cDNA)
preparation
PBMCs (1 106 cells/ml) from the patient were
cultured for 72 hours in Roswell Park Memorial
Institute (RPMI) (Gibco) culture medium supple-
mented with þ1% penicillin/streptomycin, þ1%
GlutaMAX and þ8% foetal calf serum. PBMCs
were cultured either in medium alone or in the pres-
ence of dexamethasone (10 mM, Pharmacy LUMC)
and interferon (IFN)-g (200 U/ml, PeproTech), to
increase C1QA/B/C expression.13 After 72 hours
RNA was isolated from the PBMCs using the
mirVana microRNA isolation kit (Life
Technologies catalogue no. AM1561) according to
the manufacturer’s protocol. The isolated RNA
was subsequently treated with DNase I,
Amplification Grade (Invitrogen), and cDNA was
synthesized using SuperScript III (200U/ml,
Invitrogen).
Ion Torrent sequencing
An AmpliSeq custom panel (Thermo Fisher
Scientific, Waltham, MA, USA) was used to
sequence the coding regions of the following
genes: C4A, C2, C1S, C1R, DNASE1L3, TREX1,
MASP2, C4B, C1QA, C1QB, C1QC, PLG and
SERPING1. Library preparation and sequencing
was performed according to manufacturer proto-
cols on an S5 system (Thermo Fisher Scientific).
Polymerase chain reaction (PCR)
To confirm mutations found by Ion Torrent
sequencing and to test whether the mutations
found were on different alleles, mutation (allele)-
specific PCR was used on the patient’s cDNA.
We used the Rapid Cycler technology (BioFire
Diagnostics, Salt Lake City, UT, USA) with 50
cycles of five seconds at 95C, 30 seconds at 65C
and 60 seconds at 72C, in 15 ml of PCR buffer
containing 2 U of Taq polymerase (Promega
Benelux, Leiden, the Netherlands), 2 U of
TaqStart antibody (Takara, Mountain View, CA,
USA), 50 ng of each primer, 200mM for each of the
deoxyribonucleoside triphosphates, 50mM KCl,
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1.5mM MgCl2, 0.1% (v/v) Triton X-100, 10mM
Tris, pH 9.0 at 25C, in 10 ml glass capillaries
(BioFire Diagnostics). The C1QC primer sequences
for cDNA are shown in Table 1.
Sanger sequencing
PCR products from genomic DNA and cDNA
were sequenced on an automated fluorescent
sequencer (ABI 3730; Thermo Fisher Scientific)
with the use of Big Dye Terminator (v.1.1) chemis-
try (Thermo Fisher Scientific). Primers used for
sequencing were the same as those used for the
PCR. For cDNA numbering, the A of the ATG
translation initiation codon was taken as 1. This




Here we describe a Dutch woman born from two
Caucasian non-consanguineous parents. She has
two half brothers who are reported to be healthy.
Her C1q deficiency was diagnosed at the age of 5.
The patient has encountered many different clinical
problems, including infections and neurological,
vascular and bone complications. Her case will be
presented per disease manifestation and not in
chronological order. The use of FFP throughout
her medical history will be discussed separately.
Infections
During the first year of her life, the patient suffered
from recurring otitis and gingivitis. She was
reported to be a non-responder for hepatitis B vac-
cination. Additionally, at the age of 6 she devel-
oped sepsis caused by Streptococcus pneumoniae.
She experienced a herpes zoster infection when
she was 12 years old. During adulthood, she was
hospitalized with hemophagocytic lymphohistiocy-
tosis (confirmed with a bone marrow biopsy) and
pancytopenia, which was potentially induced by
co-trimoxazole. During this hospitalization various
infections were also diagnosed and treated accord-
ingly: Escherichia coli and candidiasis.
Sanger sequencing From the age of 4, clinical symp-
toms were compatible with SLE-like disease, with
butterfly rash. At age 11 years, the diagnosis of
SLE was established based on butterfly rash, oral
ulcers, thrombocytopenia and positive antibodies
(positive antinuclear antibodies, positive anti-Sm
and positive anti-SSA). Anti-double-stranded
DNA and antiphospholipid antibodies were not pre-
sent. Furthermore, she experienced recurrent fevers
with lymphadenopathy and vasculitis lesions of the
hand and feet. Initially, the SLE was treated with
hydroxychloroquine and prednisolone, with serious
side effects, including weight gain (cushingoid),
osteoporosis and bone infarctions. Furthermore,
symptoms of fatigue, headache and arthralgia
occurred during attempts to taper prednisolone
treatment. On the basis of the diagnosis of SLE in
combination with the earlier established C1q defi-
ciency, and the side effects and inability to taper
prednisolone, treatment with FFP was initiated.
Cerebral involvement
When the patient was 14 years old she was hospi-
talized with a fever, paraesthesia and difficulties
with speech. Infectious causes were excluded.
Magnetic resonance imaging scans of the brain
were normal. Electroencephalogram showed left
parieto-occipital irritative abnormalities. Liquor
analysis revealed enhanced protein content without
elevated cell count. With the working diagnosis of
transient ischaemic attack (TIA)/partial epileptic
seizure due to cerebral vasculitis, she was treated
with prednisolone and carbasalate calcium.
Subsequent visits at the age of 24, 25 and 28 at
the Leiden University Medical Center multidiscip-
linary neuropsychiatric SLE (NPSLE) clinic14 for
anxiety and difficulty with speech did not reveal
signs of active inflammatory NPSLE.
Vascular problems
At the age of 26 the patient developed a deep
venous thrombosis, although no antiphospholipid
antibodies were detected (anticardiolipin antibodies
IgM/immunoglobulin G (IgG), anti-b2 glycopro-
tein I IgM/IgG and lupus anticoagulant). When
the patient was 27 years old, she experienced a
spontaneous abortion at a gestation of 8 weeks.
Bone lesions
At the age of 9 she developed an avascular necrosis
of the humerus which led to a destructed right
Table 1 C1QC primer sequences
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shoulder. During recent years she developed exten-
sive bone infarctions around the knee. Because of
the osteonecrosis, she underwent total hip replace-
ment surgery at the age of 29. Osteoporosis had
already been identified during childhood.
Therapy
Initially, prednisolone and hydroxychloroquine
were used to treat the SLE. Because the patient
was unable to taper the prednisolone and she was
already diagnosed with C1q deficiency, FFP treat-
ment was started at the age of 11 with 15ml per kg.
The FFP infusions were administered one to four
times per month and were preceded by clemastine
and prednisolone intravenously. CP activity was
measured preceding each FFP infusion. When
FFP took place each week, the CP activity was
80% to 90%; when the FFP was every two
weeks, the CP activity dropped below 50%, which
was in line with previous reports.15 Anti-C1q anti-
bodies were detectable, though not increased. There
were several adverse reactions to the FFP therapy,
ranging from mild urticarial to anaphylactic reac-
tion. Despite these adverse reactions, the patient
preferred the FFP therapy because of reduction of
fatigue, arthralgia and number of infections.
However, because of a serious anaphylactic reac-
tion at the age of 25, FFP treatment was discon-
tinued and her current treatment regimen consists
of hydroxychloroquine, azathioprine, low-dose
prednisolone, clopidogrel, bisphosphonates and
cholecalciferol.
Complete absence of C1q in serum
Western blot analyses of serum from the patient
and NHS (pool of four healthy adults) were ana-
lysed for the presence of C1q. The same amount of
serum was applied in native, denaturing or reducing
conditions. Only in the NHS lane was C1q detected
(Figure 1 (a)–(c)). Therefore, we confirmed the
absence of circulating C1q in the patient’s serum.
Additionally, her serum was tested for C1q in
ELISA format, next to 21 healthy female controls
(ages 26–32 years). The C1q levels in the healthy
controls had an average of 171 mg/ml C1q, whereas
in the patient’s serum the C1q level was below the
detection limit of 0.065 mg per ml (Figure 1(d)).
Sequencing
To determine what the mutation(s) are in this
patient and where they are located, DNA and
RNA sequencing was performed. Two previously
described mutations were identified in the patient’s
C1QC gene: c.100G>A p.(Gly34Arg) and
c.205C>T p.(Arg69X). With RNA sequencing we
confirmed that both mutations were heterozygous,
meaning these mutations are compound heterozy-
gous (Figure 2).
Discussion
C1q deficiency is a rare genetic disorder which is
often accompanied by development of SLE. The
Figure 1 C1q protein analysis shows no C1q in the patient’s serum. Western blot analysis of serum from the patient and a control
(normal human serum). The serum samples were prepared under (a) reducing condition, (b) denaturing and non-reduced condition
or (c) non-reducing and non-denaturing conditions. Measurement of C1q with enzyme-linked immunosorbent assay in the serum
of healthy female age-matched controls (n¼ 21) and (d) the patient.
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patient described here was already diagnosed both
with C1q deficiency and SLE in early childhood.
She has suffered from recurrent infections, which
is also a hallmark of C1q deficiency.12 Another
part of her medical history involves bone lesions.
Interestingly, osteoclasts are able to produce and
secrete C1q, which could be suggestive of a direct
relation between C1q deficiency and development
of bone lesions, although the function of C1q is
unknown in this environment.16 However, it is
unclear and difficult to determine whether these
bone lesions and recurrent infections are a conse-
quence of the C1q deficiency, the SLE, the steroid
treatment, or a combination of these factors. C1q is
important in the clearance of apoptotic material
and immune complexes. In addition to activation
of the CP of the complement system, C1q has vari-
ous functions independent of CP activation.3
Previously, 15 C1q-deficient patients with
NPSLE have been described in literature, with the
most frequent presenting symptom being seizures
(67%), which is much higher than observed in con-
ventional SLE patients.12 Cerebral vasculitis has
also been reported in 27% of C1q-deficient
NPSLE patients. The patient described here experi-
enced neurological symptoms in adolescence and
was diagnosed as having a TIA/partial epileptic
seizure due to cerebral vasculitis. It is known that
C1q inhibits IFN production. In patients with C1q
deficiency, high IFN levels are observed in serum
and cerebrospinal fluid. Recently, it was found that
type I IFN stimulates microglia to engulf synaptic
material, resulting in synaptic loss in the central
nervous system.17,18 This could contribute to
neuropsychiatric involvement in C1q deficiency.
This patient has been treated with FFP for
almost 14 years. Shortly after infusion C1q levels
reach their maximum and rapidly decline, whereas
CP activity is sustained for a longer period of time.
Even though the C1q levels and CP activity effects
are relatively short lived, the symptomatic relief
and substantial improvement in quality of life of
the FFP treatment is sustained for several weeks.
Empirically it has been established for this patient
that two units of FFP every two weeks is most
optimal. The FFP therapy has been accompanied
by adverse events on infusion, even anaphylactoid
reactions, although anti-C1q antibodies were not
increased in this patient.
Of the C1q-deficient patients who have been
described so far, all except one have been reported
to have a homozygous mutation in the C1q genes.
Here, we report the second case of C1q deficiency
with a compound heterozygous mutation, in this
case located in C1QC: c.100G>A p.(Gly34Arg)
and c.205C>T p.(Arg69X).
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Figure 2 Compound heterozygous mutation located in the C1QC gene. RNA sequence analysis revealed heterozygous mutations
of C1QC highlighted by the red box: c.100G>A p.(Gly34Arg) and c.205C>T p.(Arg69X).
Compound heterozygous C1q deficiency







1 Beurskens FJ, van Schaarenburg RA, Trouw LA. C1q, antibodies
and anti-C1q autoantibodies. Mol Immunol 2015; 68: 6–13.
2 Lubbers R, van Essen MF, van Kooten C, Trouw LA. Production
of complement components by cells of the immune system. Clin Exp
Immunol 2017; 188: 183–194.
3 Nayak A, Ferluga J, Tsolaki AG, Kishore U. The non-classical
functions of the classical complement pathway recognition subcom-
ponent C1q. Immunol Lett 2010; 131: 139–150.
4 Chen G, Tan CS, Teh BK, Lu J. Molecular mechanisms for syn-
chronized transcription of three complement C1q subunit genes in
dendritic cells and macrophages. J Biol Chem 2011; 286:
34941–34950.
5 Stegert M, Bock M, Trendelenburg M. Clinical presentation of
human C1q deficiency: How much of a lupus? Mol Immunol 2015;
67: 3–11.
6 Schejbel L, Skattum L, Hagelberg S, et al. Molecular basis of her-
editary C1q deficiency – revisited: Identification of several novel
disease-causing mutations. Genes Immun 2011; 12: 626–634.
7 van Schaarenburg RA, Schejbel L, Truedsson L, et al. Marked vari-
ability in clinical presentation and outcome of patients with C1q
immunodeficiency. J Autoimmun 2015; 62: 39–44.
8 Afzali P, Isaeian A, Sadeghi P, et al. Complement deficiency in
pediatric-onset systemic lupus erythematosus. J Lab Physicians
2018; 10: 232–236.
9 Olsson RF, Hagelberg S, Schiller B, Ringde´n O, Truedsson L,
A˚hlin A. Allogeneic hematopoietic stem cell transplantation in
the treatment of human C1q deficiency: The Karolinska experi-
ence. Transplantation 2016; 100: 1356–1362.
10 Ekinci Z, Ozturk K. Systemic lupus erythematosus with C1q defi-
ciency: Treatment with fresh frozen plasma. Lupus 2018; 27:
134–138.
11 van Schaarenburg RA, Daha NA, Schonkeren JJ, et al.
Identification of a novel non-coding mutation in C1qB in a
Dutch child with C1q deficiency associated with recurrent infec-
tions. Immunobiology 2015; 220: 422–427.
12 van Schaarenburg RA, Magro-Checa C, Bakker JA, et al. C1q
deficiency and neuropsychiatric systemic lupus erythematosus.
Front Immunol 2016; 7: 647.
13 Moosig F, Damm F, Knorr-Spahr A, et al. Reduced expression of
C1q-mRNA in monocytes from patients with systemic lupus ery-
thematosus. Clin Exp Immunol 2006; 146: 409–416.
14 Zirkzee EJ, Steup-Beekman GM, van der Mast RC, et al.
Prospective study of clinical phenotypes in neuropsychiatric sys-
temic lupus erythematosus; multidisciplinary approach to diagno-
sis and therapy. J Rheumatol 2012; 39: 2118–2126.
15 Mehta P, Norsworthy PJ, Hall AE, et al. SLE with C1q deficiency
treated with fresh frozen plasma: A 10-year experience.
Rheumatology (Oxford) 2010; 49: 823–824.
16 Teo BH, Bobryshev YV, Teh BK, Wong SH, Lu J. Complement
C1q production by osteoclasts and its regulation of osteoclast
development. Biochem J 2012; 447: 229–237.
17 Bialas AR, Presumey J, Das A, et al. Microglia-dependent synapse
loss in type I interferon-mediated lupus. Nature 2017; 546:
539–543.
18 Santer DM, Hall BE, George TC, et al. C1q deficiency leads to
the defective suppression of IFN-alpha in response to nucleopro-
tein containing immune complexes. J Immunol 2010; 185:
4738–4749.
Compound heterozygous C1q deficiency
R Lubbers et al.
1260
Lupus
